

# Hans-Michael Kvasnicka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5005367/publications.pdf>

Version: 2024-02-01

34  
papers

4,076  
citations

304368

22  
h-index

433756

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

3113  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	0.6	814
2	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. <i>Blood</i> , 2007, 110, 1092-1097.	0.6	808
3	European consensus on grading bone marrow fibrosis and assessment of cellularity. <i>Haematologica</i> , 2005, 90, 1128-32.	1.7	545
4	The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. <i>Blood Cancer Journal</i> , 2018, 8, 15.	2.8	404
5	Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. <i>Blood</i> , 2013, 121, 1720-1728.	0.6	281
6	Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. <i>Blood</i> , 2011, 117, 5710-5718.	0.6	163
7	Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells. <i>Cancer Immunology Research</i> , 2014, 2, 741-755.	1.6	134
8	Prognostic factors in idiopathic (Primary) osteomyelofibrosis. <i>Cancer</i> , 1997, 80, 708-719.	2.0	90
9	Prodromal myeloproliferative neoplasms: The 2008 WHO classification. <i>American Journal of Hematology</i> , 2010, 85, 62-69.	2.0	84
10	Initial (Latent) Polycythemia vera with Thrombocytosis Mimicking Essential Thrombocythemia. <i>Acta Haematologica</i> , 2005, 113, 213-219.	0.7	72
11	Bone Marrow Histopathology in Myeloproliferative Disorders-Current Diagnostic Approach. <i>Seminars in Hematology</i> , 2005, 42, 184-195.	1.8	68
12	Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study. <i>Histopathology</i> , 2016, 68, 905-915.	1.6	67
13	The Impact of Clinicopathological Studies on Staging and Survival in Essential Thrombocythemia, Chronic Idiopathic Myelofibrosis, and Polycythemia Rubra Vera. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 362-371.	1.5	63
14	Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. <i>Journal of Hematology and Oncology</i> , 2018, 11, 42.	6.9	63
15	Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. <i>Experimental Hematology</i> , 2007, 35, 1719-1722.	0.2	55
16	Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients. <i>American Journal of Hematology</i> , 2002, 70, 283-291.	2.0	50
17	Proteome activity landscapes of tumor cell lines determine drug responses. <i>Nature Communications</i> , 2020, 11, 3639.	5.8	47
18	Clinicopathological Criteria for Differential Diagnosis of Thrombocythemias in Various Myeloproliferative Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 219-230.	1.5	40

#	ARTICLE	IF	CITATIONS
19	Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature. <i>Oncotarget</i> , 2018, 9, 22236-22240.	0.8	34
20	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. <i>American Journal of Hematology</i> , 2017, 92, 1062-1067.	2.0	33
21	Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy. <i>Blood</i> , 2013, 122, 4055-4055.	0.6	29
22	Bone Marrow Fibrosis and Diagnosis of Essential Thrombocythemia. <i>Journal of Clinical Oncology</i> , 2009, 27, e220-e221.	0.8	24
23	Classification of Ph-Negative Chronic Myeloproliferative Disorders – Morphology as the Yardstick of Classification. <i>Pathobiology</i> , 2007, 74, 63-71.	1.9	21
24	WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 333-341.	1.2	19
25	Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53. <i>Oncogene</i> , 2021, 40, 4352-4367.	2.6	17
26	European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. <i>Haematologica</i> 2012;97(3):360-5 - Comment. <i>Haematologica</i> , 2012, 97, e5-e6.	1.7	15
27	Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors. <i>Oncology Letters</i> , 2018, 15, 9852-9860.	0.8	13
28	How to define treatment failure for JAK inhibitors. <i>Lancet Haematology</i> , 2017, 4, e305-e306.	2.2	9
29	Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma. <i>Cytotherapy</i> , 2018, 20, 839-850.	0.3	7
30	Effects Of Ruxolitinib Therapy On Megakaryocyte Morphology and Inflammatory Bone Marrow Reaction In Patients With Myelofibrosis. <i>Blood</i> , 2013, 122, 4056-4056.	0.6	5
31	Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. <i>BMC Research Notes</i> , 2016, 9, 454.	0.6	2
32	Differenzialdiagnose <i>BCR-ABL1</i> -negativer myeloproliferativer Neoplasien. <i>Laboratoriums Medizin</i> , 2015, 39, 301-310.	0.1	0
33	Decanucleotide Insertion Polymorphism of F7 Influences Significantly the Risk of Thrombosis in Patients with Essential Thrombocythemia. <i>Blood</i> , 2012, 120, 1730-1730.	0.6	0
34	Myeloproliferative Neoplasms. , 2020, , 146-161.		0